K. Dale

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Mustafa Sadia Alfie Ashraf Sherif Mohamed Basir Al Abaleke Abbas Abbasi Abbott Abdelaziz Abdelbadiee , E. Abaleke, M. Abbas, Sadia Abbasi +496 more

2021The Lancet289 citations Open access

Semantic Scholar

K. Dale

Most-cited papers

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%?

The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling

Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease

Quantifying the rates of late reactivation tuberculosis: a systematic review.

Estimating long-term tuberculosis reactivation rates in Australian migrants.

Gender differences in tuberculosis diagnosis, treatment and outcomes in Victoria, Australia, 2002-2015.

Whole genome sequencing for tuberculosis in Victoria, Australia: A genomic implementation study from 2017 to 2020

Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia

Mortality among tuberculosis cases in Victoria, 2002-2013: case fatality and factors associated with death.

Modelling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low Incidence Setting.

Recurrence of tuberculosis in a low-incidence setting without directly observed treatment: Victoria, Australia, 2002-2014.

Comparing tuberculosis management under public and private healthcare providers: Victoria, Australia, 2002–2015

The prevalence of tuberculosis infection among foreign-born Canadians: a modelling study

Impact of Reversion of Mycobacterium tuberculosis Immunoreactivity Tests on the Estimated Annual Risk of Tuberculosis Infection

Perspectives of Vietnamese, Sudanese and South Sudanese immigrants on targeting migrant communities for latent tuberculosis screening and treatment in low‐incidence settings: A report on two Victorian community panels

Projected Effects of Changing Global Tuberculosis Epidemiology on Mycobacterium tuberculosis Immunoreactivity Prevalence, 2024–2050

Estimating annual risk of infection with Mycobacterium tuberculosis.

Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly

Novel nitrogen-containing heterocyclics with bactericidal activity against Mycobacterium tuberculosis

Gender differences in tuberculosis diagnosis and treatment in an industrialised low-incidence setting: Victoria, Australia, 2002-2015